We narrowed to 1,066 results for: aav

#176753-AAV9

Ready-to-use AAV9 particles produced from AAV-mDlx-jGCaMP8f-WPRE (#176753). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8f-WPRE plasmid DNA. mDlx enhancer-driven expression of calcium sensor GCaMP8f in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#50474-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-hM3D(Gq)-mCherry (#50474). In addition to the viral particles, you will also receive purified pAAV-hSyn-hM3D(Gq)-mCherry plasmid DNA. hSyn-driven hM3D(Gq) receptor with an mCherry reporter for CNO-induced neuronal activation. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Oct. 21, 2024

Academic Institutions and Nonprofits only

#176754-AAV9

Ready-to-use AAV9 particles produced from AAV-mDlx-jGCaMP8m-WPRE (#176754). In addition to the viral particles, you will also receive purified AAV-mDlx-jGCaMP8m-WPRE plasmid DNA. mDlx enhancer-driven expression of calcium sensor GCaMP8m in GABA-ergic interneurons. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Feb. 24, 2023

Academic Institutions and Nonprofits only

#128315-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-GCaMP6f (#128315). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-GCaMP6f plasmid DNA. EF1a-driven, Flp-dependent expression of calcium sensor GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

March 12, 2021

Academic Institutions and Nonprofits only

#50457-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 17, 2020

Academic Institutions and Nonprofits only

#131002-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2024

Academic Institutions and Nonprofits only

#135630-AAV1

Ready-to-use AAV1 particles produced from pAAV-S5E2-dTom-nlsdTom (#135630). In addition to the viral particles, you will also receive purified pAAV-S5E2-dTom-nlsdTom plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Jan. 6, 2022

Academic Institutions and Nonprofits only

#37825-AAV2.T

Ready-to-use AAV2 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

May 29, 2019

Academic Institutions and Nonprofits only

#45580-AAV8

Ready-to-use AAV8 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

Nirao Shah, Jim Wells

Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

Nov. 13, 2025

Academic Institutions and Nonprofits only

#169256-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-Soma-jGCaMP8s (#169256). In addition to the viral particles, you will also receive purified AAV-hSyn-Soma-jGCaMP8s plasmid DNA. hSyn-driven expression of soma-targeted calcium sensor GCaMP8s (more sensitive). These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

July 21, 2023

Academic Institutions and Nonprofits only

#105678-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR1-FusionRed (#105678). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR1-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Sept. 24, 2020

Academic Institutions and Nonprofits only

#100799-AAV1

Ready-to-use AAV1 particles produced from pAAV-TREtight-mTagBFP2-B19G (#100799). In addition to the viral particles, you will also receive purified pAAV-TREtight-mTagBFP2-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus; to be coinjected with pAAV-syn-FLEX-splitTVA-EGFP-tTA (Addgene# 100798). These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Liu et al Nature. 2017 Aug 31;548(7669):582-587. d

Dec. 18, 2018

Academic Institutions and Nonprofits only

#37825-AAV6.T

Ready-to-use AAV6 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 16, 2025

Academic Institutions and Nonprofits only

#45580-AAV1

Ready-to-use AAV1 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

Nirao Shah, Jim Wells

Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

Dec. 3, 2020

Academic Institutions and Nonprofits only

#135631-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-GFP-fGFP (#135631). In addition to the viral particles, you will also receive purified pAAV-S5E2-GFP-fGFP plasmid DNA. Bicistronic expression of GFP and membrane-targeted GFP under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Sept. 27, 2023

Academic Institutions and Nonprofits only

#83899-AAV9

Ready-to-use AAV9 particles produced from pAAV-mDlx-GCaMP6f-Fishell-2 (#83899). In addition to the viral particles, you will also receive purified pAAV-mDlx-GCaMP6f-Fishell-2 plasmid DNA. mDlx-driven expression of GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Dimidschstein et al Nat Neurosci. 2016 Oct 31. doi: 10.1038/

Nov. 13, 2020

Academic Institutions and Nonprofits only

#208717-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-GRAB_g5-HT3.0 (#208717). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_g5-HT3.0 plasmid DNA. Synapsin-driven expression of GRAB_g5-HT3.0 sensor. These AAV preparations are suitable purity for injection into animals.

Yulong Li

Deng et al Nat Methods. 2024 Apr;21(4):692-702. doi

Sept. 22, 2025

Academic Institutions and Nonprofits only

#50465-AAV5.T

Ready-to-use AAV5 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

June 12, 2019

Academic Institutions and Nonprofits only

#20071-AAV9

Ready-to-use AAV9 particles produced from pACAGW-ChR2-Venus-AAV (#20071). In addition to the viral particles, you will also receive purified pACAGW-ChR2-Venus-AAV plasmid DNA. CAG-driven, channelrhodopsin fused to Venus for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karel Svoboda

Leopoldo et al Nature. 2009 Jan 18.

March 15, 2018

Academic Institutions and Nonprofits only

#55641-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Aug. 28, 2020

Academic Institutions and Nonprofits only

#37825-CAP-B22

Ready-to-use AAV CAP-B22 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the CAP-B22 serotype, which permits efficient transduction of neurons and astrocytes in the central nervous system. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Nov. 8, 2023

Academic Institutions and Nonprofits only

#121675-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Dec. 15, 2020

Academic Institutions and Nonprofits only

#51506-AAV5

Ready-to-use AAV5 particles produced from AAV phSyn1(S)-tdTomato-WPRE (#51506). In addition to the viral particles, you will also receive purified AAV phSyn1(S)-tdTomato-WPRE plasmid DNA. hSyn-driven tdTomato expression. These AAV preparations are suitable purity for injection into animals.

Hongkui Zeng

Oh et al Nature. 2014 Apr 10;508(7495):207-14. do

Nov. 29, 2021

Academic Institutions and Nonprofits only

#50465-AAV8.T

Ready-to-use AAV8 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2019

Academic Institutions and Nonprofits only

#169258-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-Soma-jGCaMP8f (#169258). In addition to the viral particles, you will also receive purified AAV-hSyn-Soma-jGCaMP8f plasmid DNA. Synapsin-driven neuronal expression of soma-targeted calcium sensor jGCaMP8f. These AAV preparations are suitable purity for injection into animals.

Marianne Fyhn

Grodem et al Nat Commun. 2023 Feb 4;14(1):608. doi: 1

Sept. 27, 2023

Academic Institutions and Nonprofits only

#37825-AAV5.T

Ready-to-use AAV5 trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

May 29, 2019

Academic Institutions and Nonprofits only

#99121-AAV1

Ready-to-use AAV1 particles produced from pAAV-ihSyn1-DIO-tTA (#99121). In addition to the viral particles, you will also receive purified pAAV-ihSyn1-DIO-tTA plasmid DNA. Cre-dependent expression of the tet-off transactivator from an inducible synapsin promoter. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

April 4, 2019

Academic Institutions and Nonprofits only

#135635-AAV9

Ready-to-use AAV9 particles produced from pAAV-S5E2-Gq-P2A-dTomato (#135635). In addition to the viral particles, you will also receive purified pAAV-S5E2-Gq-P2A-dTomato plasmid DNA. Expression of Gq-DREADD and dTomato (physically separate) under the control of the E2 regulatory element. These AAV preparations are suitable purity for injection into animals.

Jordane Dimidschstein

Vormstein-Schneider et al Nat Neurosci. 2020 Dec;23(12):1629-1636.

Aug. 27, 2021

Academic Institutions and Nonprofits only

#50475-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-hM4D(Gi)-mCherry (#50475). In addition to the viral particles, you will also receive purified pAAV-hSyn-hM4D(Gi)-mCherry plasmid DNA. hSyn-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Oct. 21, 2024

Academic Institutions and Nonprofits only

#112000-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSynapsin1-axon-GCaMP6f (#112000). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6f plasmid DNA. Synapsin-driven, axon-targeted GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

March 12, 2021

Academic Institutions and Nonprofits only